In a groundbreaking collaboration, Moderna, renowned for its pioneering work in mRNA medicines, including the COVID-19 vaccine, joins forces with OpenAI to integrate ChatGPT Enterprise across its operations, ushering in a new era of efficiency and innovation.
Under the visionary leadership of CEO Stéphane Bancel, Moderna has embarked on an ambitious mission to infuse AI into every aspect of its business, from research and manufacturing to legal and commercial operations.
Driven by a commitment to maximizing patient impact, Moderna’s adoption of ChatGPT Enterprise is not just a technological upgrade but a strategic move towards operational excellence. Moderna ensures that every employee equips themselves with the skills to leverage AI effectively, leading to rapid adoption and proficiency through a comprehensive transformation program.
The success story begins with mChat, an internal AI chatbot tool that quickly gained traction among employees, setting the stage for the seamless integration of ChatGPT Enterprise. With its launch, Moderna witnessed a surge in productivity as employees harnessed the power of AI to create hundreds of innovative solutions tailored to their needs.
Key milestones include the deployment of 750 GPTs company-wide, with 40% of weekly active users actively creating GPTs and engaging in 120 ChatGPT Enterprise conversations per week on average.
Dose ID, a standout application, streamlines clinical trial development by automating data analysis and augmenting decision-making processes as a GPT pilot. Additionally, ChatGPT Enterprise has empowered legal and corporate brand teams by streamlining compliance processes and enhancing storytelling capabilities.
Moderna’s commitment to AI-driven innovation and OpenAI’s cutting-edge technology set the stage for continued advancements in mRNA medicines and a positive impact on patients’ lives.
